Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 6, 2009, Pages 621-633

  Kubler I ^a   Koslowski, M J ^b   Gersemann, M ^a   Fellermann, K ^c   Beisner, J ^b   Becker, S ^b   Rothfuss, K ^a   Herrlinger, K R ^a   Stange, E F ^a   Wehkamp, J ^a,b,d  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ANTIBIOTIC AGENT; AZATHIOPRINE; BETA DEFENSIN; BETA DEFENSIN 1; BETA DEFENSIN 2; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CORTICOSTEROID; CYTOKINE; DEFENSIN; MESALAZINE; TUMOR NECROSIS FACTOR ANTIBODY; ZINC;

ADULT; ALPHA CHAIN; ARTICLE; BETA CHAIN; COLON; CROHN DISEASE; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; ILEUM; MAJOR CLINICAL STUDY; MALE; PANETH CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; AZATHIOPRINE; CROHN DISEASE; DEFENSINS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949210469     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04070.x     Document Type: Article

References (66)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 29.
2. Halfvarson J, Jess T, Magnuson A, et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006 12 : 925 33.
3. Strober W. Immunology. Unraveling gut inflammation. Science 2006 313 : 1052 4.
4. Levine AD, Fiocchi C. Immunology of inflammatory bowel disease. Curr Opin Gastroenterol 2000 16 : 306 9.
5. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl 1) i16 35.
6. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006 130 : 1054 61.
7. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Büschenfelde K-H. T cell specifity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999 44 : 812 8.
8. Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001 17 : 324 30.
9. MacPherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996 38 : 365 75.
10. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003 Jun; 15 (6) 627 34.
11. Meyer-Hoffert U, Hornef MW, Henriques-Normark B, et al. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 2008 57 : 764 71.
12. Bevins CL, Nita H, Salzman NH, Ghosh D, Huttner KM. Human defensin-5 (HD-5) transgenic mice:paneth cell expression and protection from lethal salmonella typhimurium infection. Gastroenterology 122 (Suppl. 1) 2 A.D.
13. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002 122 : 44 54.
14. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007 56 : 610 2.
15. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004 127 : 412 21.
16. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 2008 1 (Suppl. 1) S67 74.
17. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 102 : 18129 34.
18. Wehkamp J, Chu H, Shen B, et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett 2006 580 : 5344 50.
19. George MD, Wehkamp J, Kays RJ, et al. In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues. BMC Genomics 2008 9 : 209. 209.
20. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's diease. Nature 2001 411 : 603 6.
21. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53 : 1658 64.
22. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008 456 : 259 63.
23. Koslowski MJ, Kubler I, Chamaillard M, et al. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS ONE 2009 4 : e4496.
24. Kapel N, Benahmed N, Morali A, et al. Fecal beta-defensin-2 in children with inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 2009 48 : 117 20.
25. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003 9 : 215 23.
26. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007 56 : 1240 7.
27. Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006 79 : 439 48.
28. Ogushi KF, Wada AF, Niidome TF, et al. Salmonella enteritidis FliC (flagella filament protein) induces hu beta-defensin-2 mRNA production by Caco-2 cells. J Biol Chem 2001 276 : 30521 6.
29. Wehkamp J, Schmidt K, Herrlinger KR, et al. Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status. J Clin Pathol 2003 56 : 352 7.
30. Mondel M, Schroeder BO, Zimmermann K, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2008 2 : 166 72.
31. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. The induction of human beta-defensin-2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007 75 (5) 2399 407.
32. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008 151 : 528 35.
33. Schultz M, Lindstrom AL. Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2008 2 : 337 55.
34. Wehkamp J, Harder J, Wehkamp K, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004 72 : 5750 8.
35. Hosaka Y, Koslowski M, Nuding S, et al. Antimicrobial host defense in the upper gastrointestinal tract. Eur J Gastroenterol Hepatol 2008 20 : 1151 8.
36. Holzer A, Harsch S, Renner O, et al. Diminished expression of apical sodium-dependent bile acid transporter in gallstone disease is independent of ileal inflammation. Digestion 2008 78 : 52 9.
37. Gasche C, Grundtner P. Genotypes and phenotypes in Crohn's disease: do they help in clinical management? Gut 2005 54 : 162 7.
38. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell {alpha}-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 102 : 18129 34.
39. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 307 : 731 4.
40. Elphick D, Liddell S, Mahida YR. Impaired luminal processing of human defensin-5 in crohn's disease: persistence in a complex with chymotrypsinogen and trypsin. Am J Pathol 2008 172 : 702 13.
41. Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005 2 : 406 15.
42. Fishbein T, Novitskiy G, Mishra L, et al. NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008 57 : 323 30.
43. Wehkamp J, Wang G, Kubler I, et al. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol 2007 179 : 3109 18.
44. van Es JH, Jay P, Gregorieff A, et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol 2005 7 : 381 6.
45. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008 57 : 903 10.
46. Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 2009 58 : 882 3.
47. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999 163 : 6718 24.
48. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007 8 : 950 7.
49. Kovalovsky D, Refojo D, Holsboer F, Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 2000 109 : 23 9.
50. Witthoft T, Pilz CS, Fellermann K, Nitschke M, Stange EF, Ludwig D. Enhanced human beta-defensin-2 (hBD-2) expression by corticosteroids is independent of NF-kappaB in colonic epithelial cells (CaCo2). Dig Dis Sci 2005 50 : 1252 9.
51. Homma T, Kato A, Hashimoto N, et al. Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004 31 : 463 9.
52. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007 46 : 187 208.
53. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol 2008 2 : 23 34.
54. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006 7 : 349 59.
55. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005 19 : 877 90.
56. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000 95 : 3452 7.
57. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999 116 : 602 9.
58. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991 32 : 50 4.
59. Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000 32 : 245 54.
60. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003 24 : 443 51.
61. Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008 14 : 4434 9.
62. Otte JM, Zdebik AE, Brand S, et al. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept 2009 156 : 1 3.
63. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008 122 : 261 6.
64. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002 70 : 953 63.
65. Peric M, Koglin S, Kim SM, et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008 181 : 8504 12.
66. Schauber J, Rieger D, Weiler F, et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006 18 : 615 21.